However, subsequent observations found that several clinical features differ between the two entities, more specifically, that XIAP deficient patients do not develop lymphomas, and over 80% develop hemophagocytic lymphohistiocytosis (HLH), classifying XIAP deficiency as part of a familial HLH syndrome [4]. Here, XIAP is linked to lymphoma.